A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg
Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoi...
Gespeichert in:
| Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 1992-04, Vol.15 (4), p.584-589 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 589 |
|---|---|
| container_issue | 4 |
| container_start_page | 584 |
| container_title | Hepatology (Baltimore, Md.) |
| container_volume | 15 |
| creator | Fattovich, Giovanna Farci, Patrizia Rugge, Massimo Brollo, Lucio Mandas, Antonella Pontisso, Patrizia Giustina, Giuliano Lai, M. Eliana Belussi, Fabio Busatto, Graziella Balestrieri, Angelo Ruol, Arturo Alberti, Alfredo |
| description | Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoid interferon‐α in 60 patients with antibody to HBeAg and hepatitis B virus DNA–positive chronic hepatitis. Patients received 5 million U/m2 interferon three times a week for 6 mo, or no treatment. Final evaluation 18 mo after randomization showed hepatitis B virus DNA negativity and ALT normalization in 53% of treated patients and in 17% of controls (p < 0.01). The probability of sustained hepatitis B virus DNA loss was significantly higher in treated patients than in controls (p < 0.005). Blinded histological assessment revealed improvement in 50% of treated patients compared with 33% of controls. Pretreatment hepatitis B virus DNA and aminotransferase levels and histological appearance were not predictive of response.
The results of this trial indicated that marked reduction of viral replication in serum and remission of liver damage can be obtained with lymphoblastoid interferon in about 50% of patients with HBeAg antibody– and HBV DNA–positive chronic hepatitis. This rate of response is higher than that reported previously. (Hepatology 1992;15:584–589). |
| doi_str_mv | 10.1002/hep.1840150405 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72855524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72855524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4095-ce757662eed6c1e76acde8c44f7ffcecfb8db96183f0ac273be81fc722cb603d3</originalsourceid><addsrcrecordid>eNqFkMFu1DAQhi0EKkvhyg3JB8Qti-3YcXLcVoVFqgQHOEfOZNw1OHGwvaq2Jx6BV-FFeAieBKNdUW6cxuP_8z_jn5DnnK05Y-L1Dpc1byXjikmmHpAVV0JXda3YQ7JiQrOq43X3mDxJ6TNjrJOiPSNnXCne1HJF4oZGM49hcnc4UghzjsH7cszRGU-Dpf4wLbsweJNycCN1c8ZoMYb517fvP3-Uni4mO5xzorcu7yjsiuaAlsXKfXaJXlBv4Iubb-j2Ajc3T8kja3zCZ6d6Tj69ufp4ua2u3799d7m5rkCyTlWAWummEYhjAxx1Y2DEFqS02lpAsEM7Dl3D29oyA0LXA7bcghYChobVY31OXh19lxi-7jHlfnIJ0HszY9inXotWKSVkAddHEGJIKaLtl-gmEw89Z_2fkPvyl_4-5PLgxcl5P0w43uPHVIv-8qSbBMbbkjC49BdTDdNS84J1R-zWeTz8Z2i_vfrwzwq_Ad9LmXY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72855524</pqid></control><display><type>article</type><title>A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Fattovich, Giovanna ; Farci, Patrizia ; Rugge, Massimo ; Brollo, Lucio ; Mandas, Antonella ; Pontisso, Patrizia ; Giustina, Giuliano ; Lai, M. Eliana ; Belussi, Fabio ; Busatto, Graziella ; Balestrieri, Angelo ; Ruol, Arturo ; Alberti, Alfredo</creator><creatorcontrib>Fattovich, Giovanna ; Farci, Patrizia ; Rugge, Massimo ; Brollo, Lucio ; Mandas, Antonella ; Pontisso, Patrizia ; Giustina, Giuliano ; Lai, M. Eliana ; Belussi, Fabio ; Busatto, Graziella ; Balestrieri, Angelo ; Ruol, Arturo ; Alberti, Alfredo</creatorcontrib><description>Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoid interferon‐α in 60 patients with antibody to HBeAg and hepatitis B virus DNA–positive chronic hepatitis. Patients received 5 million U/m2 interferon three times a week for 6 mo, or no treatment. Final evaluation 18 mo after randomization showed hepatitis B virus DNA negativity and ALT normalization in 53% of treated patients and in 17% of controls (p < 0.01). The probability of sustained hepatitis B virus DNA loss was significantly higher in treated patients than in controls (p < 0.005). Blinded histological assessment revealed improvement in 50% of treated patients compared with 33% of controls. Pretreatment hepatitis B virus DNA and aminotransferase levels and histological appearance were not predictive of response.
The results of this trial indicated that marked reduction of viral replication in serum and remission of liver damage can be obtained with lymphoblastoid interferon in about 50% of patients with HBeAg antibody– and HBV DNA–positive chronic hepatitis. This rate of response is higher than that reported previously. (Hepatology 1992;15:584–589).</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.1840150405</identifier><identifier>PMID: 1551634</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>Philadelphia, PA: W.B. Saunders</publisher><subject>Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Biopsy ; Chronic Disease ; DNA, Viral - analysis ; Female ; Hepatitis B - immunology ; Hepatitis B - pathology ; Hepatitis B - therapy ; Hepatitis B e Antigens - analysis ; Hepatitis B virus - genetics ; Humans ; Interferon-gamma - adverse effects ; Interferon-gamma - therapeutic use ; Liver - pathology ; Male ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Hepatology (Baltimore, Md.), 1992-04, Vol.15 (4), p.584-589</ispartof><rights>Copyright © 1992 Wiley Subscription Services, Inc.</rights><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4095-ce757662eed6c1e76acde8c44f7ffcecfb8db96183f0ac273be81fc722cb603d3</citedby><cites>FETCH-LOGICAL-c4095-ce757662eed6c1e76acde8c44f7ffcecfb8db96183f0ac273be81fc722cb603d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.1840150405$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.1840150405$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5607471$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1551634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fattovich, Giovanna</creatorcontrib><creatorcontrib>Farci, Patrizia</creatorcontrib><creatorcontrib>Rugge, Massimo</creatorcontrib><creatorcontrib>Brollo, Lucio</creatorcontrib><creatorcontrib>Mandas, Antonella</creatorcontrib><creatorcontrib>Pontisso, Patrizia</creatorcontrib><creatorcontrib>Giustina, Giuliano</creatorcontrib><creatorcontrib>Lai, M. Eliana</creatorcontrib><creatorcontrib>Belussi, Fabio</creatorcontrib><creatorcontrib>Busatto, Graziella</creatorcontrib><creatorcontrib>Balestrieri, Angelo</creatorcontrib><creatorcontrib>Ruol, Arturo</creatorcontrib><creatorcontrib>Alberti, Alfredo</creatorcontrib><title>A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoid interferon‐α in 60 patients with antibody to HBeAg and hepatitis B virus DNA–positive chronic hepatitis. Patients received 5 million U/m2 interferon three times a week for 6 mo, or no treatment. Final evaluation 18 mo after randomization showed hepatitis B virus DNA negativity and ALT normalization in 53% of treated patients and in 17% of controls (p < 0.01). The probability of sustained hepatitis B virus DNA loss was significantly higher in treated patients than in controls (p < 0.005). Blinded histological assessment revealed improvement in 50% of treated patients compared with 33% of controls. Pretreatment hepatitis B virus DNA and aminotransferase levels and histological appearance were not predictive of response.
The results of this trial indicated that marked reduction of viral replication in serum and remission of liver damage can be obtained with lymphoblastoid interferon in about 50% of patients with HBeAg antibody– and HBV DNA–positive chronic hepatitis. This rate of response is higher than that reported previously. (Hepatology 1992;15:584–589).</description><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Chronic Disease</subject><subject>DNA, Viral - analysis</subject><subject>Female</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B - pathology</subject><subject>Hepatitis B - therapy</subject><subject>Hepatitis B e Antigens - analysis</subject><subject>Hepatitis B virus - genetics</subject><subject>Humans</subject><subject>Interferon-gamma - adverse effects</subject><subject>Interferon-gamma - therapeutic use</subject><subject>Liver - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFu1DAQhi0EKkvhyg3JB8Qti-3YcXLcVoVFqgQHOEfOZNw1OHGwvaq2Jx6BV-FFeAieBKNdUW6cxuP_8z_jn5DnnK05Y-L1Dpc1byXjikmmHpAVV0JXda3YQ7JiQrOq43X3mDxJ6TNjrJOiPSNnXCne1HJF4oZGM49hcnc4UghzjsH7cszRGU-Dpf4wLbsweJNycCN1c8ZoMYb517fvP3-Uni4mO5xzorcu7yjsiuaAlsXKfXaJXlBv4Iubb-j2Ajc3T8kja3zCZ6d6Tj69ufp4ua2u3799d7m5rkCyTlWAWummEYhjAxx1Y2DEFqS02lpAsEM7Dl3D29oyA0LXA7bcghYChobVY31OXh19lxi-7jHlfnIJ0HszY9inXotWKSVkAddHEGJIKaLtl-gmEw89Z_2fkPvyl_4-5PLgxcl5P0w43uPHVIv-8qSbBMbbkjC49BdTDdNS84J1R-zWeTz8Z2i_vfrwzwq_Ad9LmXY</recordid><startdate>199204</startdate><enddate>199204</enddate><creator>Fattovich, Giovanna</creator><creator>Farci, Patrizia</creator><creator>Rugge, Massimo</creator><creator>Brollo, Lucio</creator><creator>Mandas, Antonella</creator><creator>Pontisso, Patrizia</creator><creator>Giustina, Giuliano</creator><creator>Lai, M. Eliana</creator><creator>Belussi, Fabio</creator><creator>Busatto, Graziella</creator><creator>Balestrieri, Angelo</creator><creator>Ruol, Arturo</creator><creator>Alberti, Alfredo</creator><general>W.B. Saunders</general><general>Wiley</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199204</creationdate><title>A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg</title><author>Fattovich, Giovanna ; Farci, Patrizia ; Rugge, Massimo ; Brollo, Lucio ; Mandas, Antonella ; Pontisso, Patrizia ; Giustina, Giuliano ; Lai, M. Eliana ; Belussi, Fabio ; Busatto, Graziella ; Balestrieri, Angelo ; Ruol, Arturo ; Alberti, Alfredo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4095-ce757662eed6c1e76acde8c44f7ffcecfb8db96183f0ac273be81fc722cb603d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Chronic Disease</topic><topic>DNA, Viral - analysis</topic><topic>Female</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B - pathology</topic><topic>Hepatitis B - therapy</topic><topic>Hepatitis B e Antigens - analysis</topic><topic>Hepatitis B virus - genetics</topic><topic>Humans</topic><topic>Interferon-gamma - adverse effects</topic><topic>Interferon-gamma - therapeutic use</topic><topic>Liver - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fattovich, Giovanna</creatorcontrib><creatorcontrib>Farci, Patrizia</creatorcontrib><creatorcontrib>Rugge, Massimo</creatorcontrib><creatorcontrib>Brollo, Lucio</creatorcontrib><creatorcontrib>Mandas, Antonella</creatorcontrib><creatorcontrib>Pontisso, Patrizia</creatorcontrib><creatorcontrib>Giustina, Giuliano</creatorcontrib><creatorcontrib>Lai, M. Eliana</creatorcontrib><creatorcontrib>Belussi, Fabio</creatorcontrib><creatorcontrib>Busatto, Graziella</creatorcontrib><creatorcontrib>Balestrieri, Angelo</creatorcontrib><creatorcontrib>Ruol, Arturo</creatorcontrib><creatorcontrib>Alberti, Alfredo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fattovich, Giovanna</au><au>Farci, Patrizia</au><au>Rugge, Massimo</au><au>Brollo, Lucio</au><au>Mandas, Antonella</au><au>Pontisso, Patrizia</au><au>Giustina, Giuliano</au><au>Lai, M. Eliana</au><au>Belussi, Fabio</au><au>Busatto, Graziella</au><au>Balestrieri, Angelo</au><au>Ruol, Arturo</au><au>Alberti, Alfredo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>1992-04</date><risdate>1992</risdate><volume>15</volume><issue>4</issue><spage>584</spage><epage>589</epage><pages>584-589</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoid interferon‐α in 60 patients with antibody to HBeAg and hepatitis B virus DNA–positive chronic hepatitis. Patients received 5 million U/m2 interferon three times a week for 6 mo, or no treatment. Final evaluation 18 mo after randomization showed hepatitis B virus DNA negativity and ALT normalization in 53% of treated patients and in 17% of controls (p < 0.01). The probability of sustained hepatitis B virus DNA loss was significantly higher in treated patients than in controls (p < 0.005). Blinded histological assessment revealed improvement in 50% of treated patients compared with 33% of controls. Pretreatment hepatitis B virus DNA and aminotransferase levels and histological appearance were not predictive of response.
The results of this trial indicated that marked reduction of viral replication in serum and remission of liver damage can be obtained with lymphoblastoid interferon in about 50% of patients with HBeAg antibody– and HBV DNA–positive chronic hepatitis. This rate of response is higher than that reported previously. (Hepatology 1992;15:584–589).</abstract><cop>Philadelphia, PA</cop><pub>W.B. Saunders</pub><pmid>1551634</pmid><doi>10.1002/hep.1840150405</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-9139 |
| ispartof | Hepatology (Baltimore, Md.), 1992-04, Vol.15 (4), p.584-589 |
| issn | 0270-9139 1527-3350 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72855524 |
| source | MEDLINE; Wiley Journals |
| subjects | Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Biopsy Chronic Disease DNA, Viral - analysis Female Hepatitis B - immunology Hepatitis B - pathology Hepatitis B - therapy Hepatitis B e Antigens - analysis Hepatitis B virus - genetics Humans Interferon-gamma - adverse effects Interferon-gamma - therapeutic use Liver - pathology Male Medical sciences Pharmacology. Drug treatments |
| title | A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A03%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomized%20controlled%20trial%20of%20lymphoblastoid%20interferon%E2%80%90%CE%B1%20in%20patients%20with%20chronic%20hepatitis%20B%20lacking%20HBeAg&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Fattovich,%20Giovanna&rft.date=1992-04&rft.volume=15&rft.issue=4&rft.spage=584&rft.epage=589&rft.pages=584-589&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.1840150405&rft_dat=%3Cproquest_cross%3E72855524%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72855524&rft_id=info:pmid/1551634&rfr_iscdi=true |